Skip to Content
COVID-19 Resources
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 03/13/18

Information below provided by the Pharmaceutical Company.


Agent Description

AZD8186 is a phosphatidylinositol 3-kinase (PI3K) beta/delta inhibitor being developed as an oral anti-tumor agent, with an initial focus on patients with phosphatase and tensin homolog (PTEN)-deficient disease.

Mechanism of Action

PI3K inhibition


PI3K inhibitor

Molecular Targets

PI3K beta/delta


The PI3K/AKT/mTOR signaling network is a critical regulator of many cellular processes, including; normal cell proliferation, survival, and growth. Increased cellular activity of PI3 kinases, either through functional loss of the PTEN tumor suppressor protein (PI3 kinase antagonist) or PI3 kinase activation mutations, is associated with development of many tumor types and hematological malignancies. Two PI3 kinase isoforms, PI3K beta and PI3K delta, have been clinically validated as targets in a variety of cancers and malignancies

Studies of Interest

Only non-clinical proposals are being accepted for this agent.

Information collaborator would like included in investigator proposals